Development of a next-generation compound family from pre-existing materials, laying the groundwork for expanded indications and formulations
[by Ji, Yong Jun] Shaperon announced on February 19 that it has received a 바카라사이트 홍보 승리바카라 in Australia for a novel class of next-generation inflammasome inhibitors developed from its core GPCR19-based molecule platform.
The patent covers a series of compounds designed and synthesized based on the structural framework of ‘NuGel,’ a GPCR19 agonist candidate currently undergoing Phase 2 clinical trials in the United States for patients with atopic dermatitis. Through this patent grant, Shaperon has significantly strengthened its global intellectual property (IP) portfolio for its inflammation-control platform technology, thereby laying the foundation for future indication expansion and the development of diversified formulations.
This newly granted composition of matter 바카라사이트 홍보 승리바카라 extends beyond protection of a single lead candidate to encompass a broad class of hundreds of derivative compounds that share the GPCR19 core structure as a common motif. As such, it represents a strategically defensive global IP approach, proactively covering structurally novel compounds that may emerge during subsequent research and development (R&D) processes, and preempting potential design-around attempts by competitors.
This compound family has a dual mechanism that simultaneously controls tumor necrosis factor-alpha (TNF-α) production and interleukin-1 beta (IL-1β) secretion triggered by inflammasome activation. Specifically, it functions as a platform technology capable of concurrently modulating both the initiation and amplification phases of the inflammatory response through regulation of the GPCR19–P2X7–NLRP3 signaling axis.
Previously, 바카라사이트 홍보 승리바카라 agonists were developed as intravenous treatments for COVID-19 and as topical agents for atopic dermatitis, demonstrating anti-inflammatory effects and an acceptable safety profile in Phase 1 and 2 clinical trials. At present, a global Phase 2b clinical trial evaluating the topical formulation for atopic dermatitis is ongoing with U.S. Food and Drug Administration (FDA) approval.
The newly registered next-generation compound family represents a follow-up series developed to expand indications and formulations based on prior clinical research experience. The company is implementing a lifecycle-oriented IP strategy that encompasses oral dosage forms and diverse formulations, including the corresponding composition of matter 바카라사이트 홍보 승리바카라s. In addition to pharmaceutical applications, these candidate compounds are considered to have potential utility in functional cosmetics and healthcare materials. As such, they are expected to function as platform assets enabling the simultaneous expansion of both novel drug development programs and healthcare-related business segments.
This 바카라사이트 홍보 승리바카라 application has been filed simultaneously in major jurisdictions, including Korea, the United States, China, Japan, Europe, Canada, and Australia, and is currently undergoing examination and registration procedures in each territory. Shaperon aims to establish a structural market entry barrier centered on core composition of matter 바카라사이트 홍보 승리바카라s through a multi-layered IP framework that integrates composition, formulation, use, and biomarker 바카라사이트 홍보 승리바카라s. Based on a long-term 바카라사이트 홍보 승리바카라 protection system extending through the 2040s, the company intends to further reinforce its strategic positioning in global technology transfer and co-development negotiations.
"This global composition of matter patent will serve as an opportunity to systematically expand the scope of rights associated with our GPCR19-based inflammation control platform beyond the protection of a single candidate compound. We intend to cultivate this portfolio into a long-term, exclusive IP asset that can be broadly leveraged for future indication expansion, follow-on pipeline development, and global technology transfer. This patent serves as an effective mechanism to fundamentally prevent competitors from attempting to enter the market by developing compounds similar to the active ingredient of our atopic dermatitis treatment currently undergoing Phase 2b clinical trials in the U.S.," a Shaperon official said.